|Bid||134.20 x 900|
|Ask||135.42 x 1000|
|Day's Range||134.09 - 142.32|
|52 Week Range||106.86 - 175.91|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||18.98|
|Earnings Date||Oct 27, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||5.64 (4.20%)|
|Ex-Dividend Date||Oct 13, 2022|
|1y Target Est||158.85|
Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.
In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.
To get a sense of who is truly in control of AbbVie Inc. ( NYSE:ABBV ), it is important to understand the ownership...